ArticleCureus2026
Ultrasound-Guided Minimally Invasive Tenotomy Utilizing TenJet for Recalcitrant Gluteal Tendinopathy: A Six-Month Interim Analysis From a Prospective Multicenter Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic gluteal tendinopathy is characterized by failed tendon healing, collagen disorganization, and breakdown in tendon structure. Traditional conservative management involves nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and corticosteroid injections. However, next steps for recalcitrant cases are lacking consensus. The TenJet device (HydroCision, Inc., North Billerica, Massachusetts, United States), utilizing high-pressure saline to resect degenerative tissue, offers a minimally invasive option to treat gluteal tendinopathy.
methodsFrom 2022 to 2025, 46 patients with gluteal tendinopathy refractory to conservative treatment were enrolled across multiple centers with planned 24-month follow-up. Visual Analog Scale (VAS) pain score and Victorian Institute of Sport Assessment-Gluteal Questionnaire (VISA-G) patient-reported outcomes were prospectively collected via REDCap alongside demographics, treatment history, procedural details, and adverse events.
resultsThe cohort was predominantly female (44/46, 95.6%), with a mean age of 60.7±8.44 years and a mean BMI of 26.9±4.73 kg/m². The mean VAS improved from 5.81±2.02 at baseline to 3.14±2.24 at two weeks (p<0.001), 2.40±2.00 at six weeks (p<0.001), 2.17±1.87 at three months (p<0.001), and 2.10±2.10 at six months (p<0.001). VISA-G improved from 44.9±14.3 at baseline to 49.0±19.1 at two weeks (p=0.807), 62.2±15.8 at six weeks (p<0.001), 66.9±15.2 at three months (p<0.001), and 69.6±12.6 at six months (p<0.001). One patient developed an adhesive-related rash; no device malfunctions or serious complications were observed.
conclusionsUltrasound-guided minimally invasive tenotomy with TenJet was associated with significant, sustained reductions in pain and improvements in function through the six-month follow-up, with a favorable short-term safety profile for chronic gluteal tendinopathy refractory to conservative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.